Erasca Expands Management Workforce with Crucial Appointments

SAN DIEGO–(Company WIRE)–Erasca, a clinical-phase precision oncology business whose mission is to erase most cancers and that is singularly centered on advancing therapies for patients with RAS/MAPK pathway-driven cancers, announced the expansion of its management workforce with vital hires in finance, small business growth, functions, lawful, regulatory, manufacturing, clinical pharmacology and facts science.

“Over the earlier couple years, we have significantly expanded our pipeline of precision oncology products candidates at Erasca,” mentioned Jonathan E. Lim, M.D., Erasca’s chairman, CEO and co-founder. “The growth of our leadership team and employees during our organization will greatly enhance our capacity to proceed to progress our novel plans for the possible reward of sufferers with most cancers. We are delighted to carry on to recruit seasoned business leaders who not only are remarkable at what they do, but also are determined by our bold mission to erase cancer.”

About Brian Baker, CPA

Mr. Baker joined Erasca as senior vice president of finance. With additional than 25 a long time of field encounter, he has provided govt stage economical skills to both general public and personal biotechnology providers, such as Turning Point Therapeutics (TPTX), Cleave Biosciences and Phenomix Corporation. Prior to Erasca, Mr. Baker most just lately served as senior vice president of finance and administration at TPTX, in which he led all corporate accounting, finance and arranging things to do. He performed a crucial part in TPTX’s progress from a smaller private enterprise into a multibillion-dollar public business and served finish 5 financings with blended proceeds in excessive of $1.3 billion, which include a $191 million initial general public providing in April 2019.

Mr. Baker gained his B.S. and M.S. degrees from San Diego Point out College and is an active certified public accountant in the condition of California.

About Rachel Cervantes, Ph.D.

Combining above a decade of knowledge in organization improvement with a solid science background, Dr. Cervantes is Erasca’s vice president of small business advancement. She joined Erasca from GW Pharmaceuticals, in which she was dependable for creating the company’s exterior innovation method and primary its partnering pursuits from prospect identification by way of arrangement execution. Prior to GW, Dr. Cervantes held very similar roles at Artificial Genomics, Egalet Company and Inovio Prescription drugs. In these roles she negotiated acquire-side and offer-side R&D deals, led cross-practical teams in producing and implementing therapeutic region tactic and set up important professional partnerships. Dr. Cervantes started her profession at Merck, the place she held roles of increasing duty in project and portfolio management, promoting and business enterprise development.

Dr. Cervantes gained a Ph.D. in molecular biology from the University of Cincinnati, an MBA from the Wharton University and a B.A. from the University of Hawai’i at Manoa.

About Nik Chetwyn, Ph.D.

As senior vice president of operations, Dr. Chetwyn brings in excess of 20 many years of experience in drug progress to Erasca, where by he works with our proficient researchers and staff members in the pharmaceutical development and functions (CMC), data engineering, operations and services, top quality assurance, and portfolio and plan leadership teams. Dr. Chetwyn has worked at a number of key pharmaceutical providers, which include GlaxoSmithKline, Pfizer and Genentech, spanning specialized improvement from discovery to new drug software (NDA) filings (Wellbutrin®, Erivedge® and Cotellic®) and transfer to commercial groups. Upon signing up for Genentech in 2006, he served create the compact molecule drug progress group and drive the major expansion of specialized and drug producing abilities. In the course of his Genentech tenure, Dr. Chetwyn served on various governance committees, was a technical improvement staff leader, and represented Genentech on the board of administrators for the Allotrope Basis. Prior to signing up for Erasca, he was the co-founder and president of MindScienceConnection, Inc., a approach and management growth organization that targeted on partnering with biopharmaceutical companies to navigate the exceptional difficulties of developing and keeping thriving research cultures even though creating the scientific leaders of the long term.

Dr. Chetwyn gained his M.S. and Ph.D. in pharmaceutical chemistry from the College of Kansas and his B.Sc. in chemical and pharmaceutical sciences from the University of Sunderland.

About Ebun Garner, J.D.

Mr. Garner is Erasca’s standard counsel and corporate secretary. He has represented publicly traded everyday living science organizations for above 20 many years and has served as an in-residence counsel considering that 2005. Throughout his job, Mr. Garner has been normal counsel or assistant common counsel at early-stage biopharmaceutical providers and a medical device firm, which includes Imbria Prescription drugs, Neurocrine Biosciences, Acadia Prescribed drugs and Alphatec Spine. At each and every organization, he delivered authorized guidance with respect to product or service growth, company improvement, company finance and community enterprise reporting. Prior to his in-residence positions, he was a corporate affiliate at the New York business of the legislation business of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo.

Mr. Garner earned a B.A. in economics from the College of Pennsylvania and a J.D. from New York University Faculty of Law.

About Chandra Lovejoy

Ms. Lovejoy joined Erasca as senior vice president of regulatory affairs, bringing 20 decades of international drug advancement knowledge, ranging from pre-investigational new drug routines by NDA submission and post-approval. Her profession has concentrated on oncology and has included drug/diagnostic enhancement and novel demo styles and endpoints. She joined Erasca from G1 Therapeutics, exactly where she was vice president of regulatory affairs and led health and fitness authority negotiations ensuing in US Meals and Drug Administration (Food and drug administration) breakthrough therapy designation and NDA acceptance for Cosela™. Ms. Lovejoy beforehand served as senior vice president, global regulatory affairs and head of top quality at Sierra Oncology and vice president of global regulatory affairs at Endocyte. Earlier in her vocation, she held roles of raising obligation at Genentech, together with as regulatory lead for Avastin®, and formerly was at Avi BioPharma.

Ms. Lovejoy has an M.S. in regulatory affairs from San Diego Point out College and a B.S. in organizational actions from the College of San Francisco.

About Minli Xie, Ph.D.

Dr. Xie joined Erasca as vice president of pharmaceutical progress and functions bringing additional than 20 years of working experience in drug advancement from discovery prospect assortment via registration and start. Prior to Erasca, she was 1 of the first 20 staff at Myovant Sciences, serving as vice president of pharmaceutical operations and development, the place she developed the CMC organization and oversaw the CMC functions that assisted help the prosperous improvement and approval of Orgovyx® and the blend product, Myfembree®, for a number of indications. Formerly, Dr. Xie was head of little molecule complex operations at Medivation, and her team’s do the job enabled the registration and approval of Talzenna®. She also created and led the small molecule pharmaceutics staff at Genentech, supporting the small molecule study and progress assignments, like Erivedge® and Cotellic®. She also labored at Bristol Myers Squibb and DuPont Merck in roles of expanding responsibility.

Dr. Xie has a Ph.D. in pharmaceutical chemistry and a B.S. in chemistry, both from the College of Kansas.

About Dawei Xuan, Ph.D.

Dr. Xuan serves as Erasca’s vice president of clinical pharmacology, bringing more than 20 several years of expertise in drug discovery and growth. He joined Erasca from Turning Place Therapeutics (TPTX), in which he was vice president of clinical pharmacology and a member of the leadership team. He was dependable for general system and execution of scientific pharmacology options to guidance the pipeline at TPTX, exactly where he helped progress repotrectinib into a registrational demo and accomplish Food and drug administration breakthrough treatment designation for the cure of individuals with TKI-naïve ROS1-favourable metastatic non-smaller cell lung most cancers. Prior to TPTX, Dr. Xuan worked at Pfizer for 17 decades wherever he held roles of growing obligation, most a short while ago as senior director of medical pharmacology in the Early Oncology Progress and Scientific Research (EODCR) business. During his tenure at Pfizer, he worked on many investigational medication across modest molecules, big molecules, antibody drug conjugates and bispecific antibodies. He contributed to the discovery and advancement of a few marketed medicines, which includes Eliquis®, Inspra® and Ibrance®. Before in his career, he worked for nine years in scientific pharmacokinetics and pharmacodynamics of antimicrobial agents at the Heart for Anti-infective Investigate and Improvement at Hartford Medical center.

Dr. Xuan attained his Ph.D. in pharmaceutical sciences from the University of Connecticut and his B.S. in pharmaceutical sciences from Peking College Health and fitness Science Center.

About Jing Yi, Ph.D.

As Erasca’s vice president of data science, Dr. Yi delivers 15 decades of encounter in biometrics and drug progress. Prior to Erasca, she took on a wide variety of roles of raising accountability at Roche/Genentech, most recently as the world-wide advancement guide and group medical science director, accountable for the overarching enhancement system and system management of Tecentriq® in lung most cancers and head and neck cancer. Dr. Yi was previously a biostatistics supervisor and biometrics direct at Roche/Genentech overseeing cancer immunotherapy products and solutions throughout a broad array of most cancers kinds. She served progress the enhancement of tiragolumab in lung and head and neck cancer and Tecentriq® throughout different tumor kinds, like obtaining breakthrough therapy designation and world wide registration for bladder and lung most cancers as perfectly as several line extensions. She supported Avastin® enhancement and submit-internet marketing applications throughout a number of oncology sickness places. She also represented biometrics at the Roche lung and cancer immunotherapy portfolio amount and co-led numerous cross-oncology and cross-pharmaceutical initiatives.

Dr. Yi gained her Ph.D. in stats from the University of California, Berkeley and her B.S. in computational mathematics from the Qingdao University.

About Erasca

At Erasca, our name is our mission: To erase cancer. We are a medical-phase precision oncology enterprise singularly targeted on exploring, creating, and commercializing therapies for people with RAS/MAPK pathway-driven cancers. Our organization was co-started by primary pioneers in precision oncology and RAS focusing on to make novel therapies and combination regimens made to comprehensively shut down the RAS/MAPK pathway for the treatment of most cancers. We have assembled what we believe to be the deepest RAS/MAPK pathway-targeted pipeline in the industry. We imagine our world-course team’s capabilities and practical experience, even more guided by our scientific advisory board which features the world’s top authorities in the RAS/MAPK pathway, uniquely position us to obtain our bold mission of erasing most cancers. For additional details, please go to www.erasca.com.

Erasca is a trademark of Erasca, Inc.